Welcome to our dedicated page for Hinge Health news (Ticker: HNGE), a resource for investors and traders seeking the latest updates and insights on Hinge Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hinge Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hinge Health's position in the market.
Hinge Health (NYSE: HNGE) has announced the pricing of its Initial Public Offering (IPO), offering 13,666,000 shares of Class A common stock at $32.00 per share. The offering consists of 8,522,528 shares from Hinge Health and 5,143,472 shares from selling stockholders. Trading is set to begin on the NYSE on May 22, 2025, under the ticker "HNGE".
The selling stockholders have granted underwriters a 30-day option to purchase up to 2,049,900 additional shares. The company plans to use the proceeds primarily to cover tax obligations related to restricted stock units. Morgan Stanley, Barclays, and BofA Securities are serving as lead book-running managers for the offering.
